COCP

Cocrystal Pharma, Inc.
CAPPED RATING

Cocrystal Pharma, Inc. (COCP) is rated C (2.2/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Revisions (C+); its weakest is Profitability (D). The rating has held at C for 7 weeks.

Quantitative Factor Evaluation • Updated

Overall Rating
2.2 / 5.0
C
Value
C+
Factor Score 2.6 / 5.0
Growth
D+
Factor Score 1.7 / 5.0
Profitability
D
Factor Score 1.4 / 5.0
Momentum
C+
Factor Score 2.6 / 5.0
Revisions
C+
Factor Score 2.6 / 5.0

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Underlying Financial Metrics

P/E Ratio -2.2
EV / EBITDA -1.9
Rev Growth YoY N/A
Gross Margin 0.0%
Price Return 3M -8.0%
Price Return 12M -6.4%
Catalyst Signal 0.00
Market Cap $19.8M
TTM Revenue $330.0K
Price / Sales 60.1
ROE -311.7%

Historical Factor Score Progression

Held C for 7 weeks
Date Value Growth Profitability Momentum Revisions Overall
2026-11-11 C+ (2.6) D+ (1.7) D (1.4) C+ (2.6) C+ (2.6) C (2.2)
2026-11-04 C+ (2.6) D+ (1.7) D (1.4) C+ (2.8) C+ (2.7) C (2.2)
2026-10-28 C+ (2.7) D+ (1.6) D (1.5) B- (2.9) C+ (2.7) C (2.3)
2026-10-21 C+ (2.7) D+ (1.6) D (1.4) C+ (2.6) C+ (2.6) C (2.2)
2026-10-14 C+ (2.6) D+ (1.6) D (1.4) C+ (2.7) C+ (2.6) C (2.2)
Page 1 of 4